Correcting deficiency can improve muscle strength and reduce pain, though effects are most pronounced in individuals with baseline deficiency
: ,
Enhanced Appetite Control: The appetite-suppressing effects of GLP-1 can be a game-changer, making it easier to stick to a calorie deficit and manage cravings
Developer: Eli Lilly and Company Classification: Triple Agonist (GIP/GLP-1/Glucagon receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials Expected FDA Approval: Q3 2026 to Q1 2027 Developer: Boehringer Ingelheim Classification: Dual Agonist (Glucagon/GLP-1 receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials (SYNCHRONIZE program) Regulatory Status: FDA Breakthrough Therapy designation for MASH Retatrutide emerged from Eli Lillys research into multi-receptor agonism
The ancestry composition of UKBB participants was defined based on self-reported ethnicities and genetic PCA
You can support natural GLP-1 secretion by: Eating more protein and fiber (e.g., legumes, whole grains, eggs, yogurt) Consuming healthy fats (e.g., avocado, olive oil, nuts) Exercising regularly Avoiding rapid spikes in blood sugar (e.g., reduce processed carbs and sugar) Intermittent fasting or time-restricted eating may also help improve GLP-1 levels and sensitivity Is GLP-1 safe for long-term use